Gabriel Schnetzler

Roche (Switzerland) — Switzerland

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index618citations86works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(25), Cancer Immunotherapy and Biomarkers(17), Computational Drug Discovery Methods(17), Sexual function and dysfunction studies(16), Protein Kinase Regulation and GTPase Signaling(10)

Publications86 total

Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Molecular Cancer Therapeutics·2025
822P Evaluating ctDNA as a predictive biomarker in a phase I clinical trial of mosperafenib in BRAFV600E-mutant colorectal cancer
Annals of Oncology·2025
Preliminary safety, pharmacokinetics, and clinical activity of RG6344 in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Journal of Clinical Oncology·2025· 1 cited
Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia
Blood Neoplasia·2025· 3 citedOpen Access
Abstract CT017: A phase I study evaluating safety, pharmacokinetics, and clinical activity of the novel, paradox breaker BRAF inhibitor RG6344 in patients with BRAF V600-mutant solid tumors
Cancer Research·2025
Abstract 1601: Advancing cancer immunotherapy: Unveiling the potential of PD-L1-targeted IFN-α2a dutaflip molecule through patient-derived tumor explants
Cancer Research·2025
Abstract 3416: Advancing cancer immunotherapy: PD-L1-targeted IFNa2a fusion protein RO7694744
Cancer Research·2025
Abstract 5606: The novel brain-penetrant paradox breaker BRAF inhibitor RG6344 manifests exceptional activity in BRAF mutant colorectal cancers
Cancer Research·2025
Supplementary Figure 4 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Supplementary Figure 2 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Table 1 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Table 3 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Table 4 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Supplementary Figure 1A and 1B from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Supplementary Figure 3 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Table S1. from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Table 2 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Figure 1 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Figure 2 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Data from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
page 1 of 5Next →

Frequent Co-authors

Tara Symonds(11), Christophe Boetsch(10), Maria Amann(9), Vaios Karanikas(9), Jan Eckmann(8), Piergiorgio Pettazzoni(8), Valentina Gambardella(8), Michael Ong(8), Jean‐Pascal Machiels(8), Miguel F. Sanmamed(8), Anna Spreafico(8), Daniel J. Renouf(8), Rachel Galot(8), Emiliano Calvo(8), Samira Curdt(8), Tamara Tanos(8), Kevin Smart(8), Linxinyu Xu(8), Kristoffer Staal Rohrberg(8), Jürgen Wichmann(7)